Maternal protein restriction reduces angiotensin II AT(1) and AT(2) receptor expression in the fetal rat kidney

Saleh H Alwasel1, Irram Kaleem, Vandana Sahajpal

  • 1Department of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia. sawasel10@hotmail.com

Maternal dietary protein restriction during pregnancy results in an increase in offspring blood pressure in the rat. The kidneys of the low protein (LP) rat have fewer nephrons, increased hemodynamic sensitivity to angiotensin II and lower glomerular filtration rate, suggesting altered activity of the renin-angiotensin system. Angiotensin II plays a role in nephrogenesis through the AT(1) and AT(2) receptor subtypes. The aim of this study was to determine expression levels of both subtypes during nephrogenesis. Pregnant Wistar rats were fed either a control 18% protein diet or a low 9% protein (LP) diet. A 35% reduction in nephron number (p < 0.05) associated with a 50% reduction in total glomerular volume (p < 0.001) was seen in LP rats. Renal AT(1) (p < 0.0001) and AT(2) (p < 0.0001) receptor protein expression were significantly lower in LP rats from E18 to day 10. AT(1) expression in LP rat kidneys tended to increase over time while AT(2) expression declined until day 10, when it began to increase again. Angiotensin II-regulated cell proliferation may be perturbed in the LP rat kidney during nephrogenesis which could contribute to the reduction in nephron number and the elevation in blood pressure observed in this model of programmed hypertension.

Related Concept Videos

Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...